The acceptability of data worldwide, a keen and well-qualified investigator community and sheer numbers of patients make the region a compelling choice for many drug developers.

The challenge to deliver is particularly great for smaller sponsors that may not have a local presence, or prior experience, in the region. Add to that the fact Asia is evolving rapidly to meet demand— regulators in most Asian countries are keenly aware of the importance of their role, and sponsors and vendors alike now have a much sharper focus on the region than only a few years ago when setting critical paths for their clinical development programs.

Other relevant content